Argos Therapeutics (ARGS) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- L3Harris CEO steps down amid conduct review, shares drop
Argos Therapeutics (ARGS) Nearing Complete Enrollment in the Phase III ADAPT Study, Roth Capital Notes
May 14, 2015 7:22 AM EDTRoth Capital analyst Joseph Pantginis reiterated a Buy rating and $21 price target on Argos Therapeutics (NASDAQ: ARGS) following ASCO abstracts.
Pantginis commented, "With the release of the ASCO abstracts, ARGS provided an update on enrollment progress for its ongoing Phase III ADAPT trial of... More
